Ensho Therapeutics

Focus: Ensho Therapeutics is a San Francisco-based biotech company focused on developing small molecule therapeutics targeting inflammatory bowel disease (IBD) and other immunology indications. The company operates as a pre-revenue stage biotech with an early-stage pipeline.

Immunology Gastroenterology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Ensho Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Ensho Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CA-4F

Transthyretin Amyloid Cardiomyopathy ("ATTR-CM")

N/A

Clinical Trials (1)

NCT05210010A Prospective Study to Assess the Utility of CA-4F in a Canadian Cardiology Setting

N/A

Help build intelligence for Ensho Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape drug development strategy in high-unmet-need IBD market with growing patient population
Focus on small molecule modality offers medicinal chemistry and formulation expertise development in immunology space
San Francisco location provides access to strong biotech talent ecosystem and venture capital networks

Watch Out For

No active job openings currently listed, indicating potential hiring freeze or minimal near-term growth
Pre-revenue stage with limited financial data transparency creates uncertainty around funding runway and company stability
Very early pipeline (Phase 1 stage) means long timeline to clinical validation and significant execution risk ahead

Generated by Claude from Ensho Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NSHO-101

Healthy

Phase 1

Clinical Trials (1)

NCT07403552Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

1 pipeline

Marketed

Pipeline